Search

everythinglearnresearchcommunity

for

Search:↓

Platycladi Cacumen may help treat hair loss by targeting specific proteins and pathways.

Personalized treatments for hair loss focus on specific genetic and biological pathways.

Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.

Targeting non-Smad pathways in TGF-β signaling may improve keloid treatment.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Araliadiol may promote hair growth like minoxidil without being toxic.

High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.

Hair follicle stem cells help maintain skin health and could improve skin replacement therapies.

The research identified key molecules that help hair matrix and dermal papilla cells communicate and influence hair growth in cashmere goats.

Recent findings suggest that genetic factors, immune system issues, and skin cell defects might contribute to the development of hidradenitis suppurativa.

SH-340 may improve skin barrier and help treat atopic dermatitis.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

CD34⁺ cells help heal damaged limbs by promoting blood vessel growth.

Certain immune cells worsen post-surgery gut paralysis by activating a specific immune response.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Oenocarpus bataua vegetable oil may help reduce hair loss by affecting a key gene pathway.

Ruxolitinib can cause a delayed skin reaction on the nose.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.